AM2019 EDU28 Treatment of Metastatic Prostate Cancer: Ready for Primetime?
At the PRO session for the AM2018, it was noted that community radiation oncologists are increasingly finding oligometastases as part of their practice or being referred these patients after advanced staging by medical oncology or urology. Additionally, there is increasing interest in urology to treat the prostate in men with metastatic prostate cancer. Multiple recent trials have been published or presented (including at ASTRO 2018) to begin to address these clinical scenarios, but it is sufficiently new that lack of knowledge and experience in these treatment approaches and delivery is a major issue.
This session will pair with the “Challenging Cases” session, with the oligometastatic session focusing on management of metastatic disease – radiation to primary, mets, and which hormonal agents for how long. This topic is complex and requires both research data discussion and practical application, and as such does not fit within the framework of "Challenging Cases in Prostate Cancer".
The meeting is designed to meet the interests of medical oncologists, radiation oncologists, radiation physicists, nurses, radiation therapists, radiation dosimetrists, radiation biologists, residents, and specialists.
- Describe the current evidence related to treatment of the prostate and mets for metastatic prostate cancer.
- Explore how to screen, counsel, and treat men for whom radiation is appropriate.
The following persons served as faculty for this activity:
Felix Feng, MD is employed at University of California San Francisco and receives compensation/remuneration/funding from Celgene, Genentech, Janssen Services LLC, Nutcracker Therapeutics, Zenith and holds stock options in Nutcracker Therapeutics.
Bridget Koontz MD, is employed at Duke Cancer Institute and receives compensation/remuneration/funding from Blue Earth Diagnostics and Janssen Services LLC.
Phuoc Tran, MD, PhD is employed at Johns Hopkins University School of Medicine and receives compensation/remuneration/funding from Astellas-Medivation, Bayer Healthcare, and RefleXion Medical.
Richard K. Valicenti, MD, MA, FASTRO is employed at University of California Davis School of Medicine and has no commercial interests.
Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.